MIMEDX GROUP, INC.
No SEC Form 4 filings for $MDXG in the last 30 days.
See all $MDXG insider activity →Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).
Sanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.
MiMedx Group (Nasdaq: MDXG) filed an 8-K/A amending its July 29, 2026 report to correct Sanara and MiMedx termination fee amounts. It also describes a merger where Sanara shareholders receive $33.00 cash per share plus 0.4735 shares of MiMedx common stock. MiMedx will issue stock and file an S-4.
Over the past 7 days, alphai's AI scored 2 news stories mentioning MDXG (MIMEDX GROUP, INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent MDXG coverage spans mergers & acquisitions, earnings and market movers.
MDXG faces valuation and volatility risk tied to the stock component of the fixed-exchange offer.
Sanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.
The merger consideration and corrected termination fee are direct inputs to valuation and deal-arbitrage positioning in MDXG.
Sanara MedTech Inc. (SMTI) filed Amendment No. 1 to its Form 8-K to correct Item 1.01 termination-fee amounts: the fee was misstated as $22,540,785.00 instead of $9,660,336.00, and vice versa for MiMedx Group, Inc. The merger terms remain unchanged. Under the merger, SMTI shareholders receive $33.00 cash and 0.4735 shares of MiMedx common stock per share.
Sanara MedTech (Nasdaq: SMTI) reported Q2 2026 net revenue of $28.1 million, up 9% year over year, with gross profit of $26.2 million and gross margin of 93%. It posted a net loss from continuing operations of $0.4 million ($0.05 per diluted share). Cash was $15.4 million and long-term debt $46.5 million. After quarter-end, Sanara said it expects to be acquired by MIMEDX, subject to closing conditions.
alphai scores every news story that mentions MDXG with an AI model for sentiment and relevance, and aggregates insider trades from MIMEDX GROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).
6 min readSanara MedTech Inc. (SMTI) reported Q2 2026 revenue up 9% to $28.1M, driven by soft tissue repair products, with gross margin at 93%. Adjusted EBITDA increased to $5.0M, but higher SG&A and interest contributed to a $0.4M net loss. The company also announced a pending merger with MiMedx Group and reorganized into a single surgical segment.
1 min readMiMedx Group (Nasdaq: MDXG) filed an 8-K/A amending its July 29, 2026 report to correct Sanara and MiMedx termination fee amounts. It also describes a merger where Sanara shareholders receive $33.00 cash per share plus 0.4735 shares of MiMedx common stock. MiMedx will issue stock and file an S-4.
6 min readSanara MedTech Inc. (SMTI) filed Amendment No. 1 to its Form 8-K to correct Item 1.01 termination-fee amounts: the fee was misstated as $22,540,785.00 instead of $9,660,336.00, and vice versa for MiMedx Group, Inc. The merger terms remain unchanged. Under the merger, SMTI shareholders receive $33.00 cash and 0.4735 shares of MiMedx common stock per share.
4 min readSanara MedTech (Nasdaq: SMTI) reported Q2 2026 net revenue of $28.1 million, up 9% year over year, with gross profit of $26.2 million and gross margin of 93%. It posted a net loss from continuing operations of $0.4 million ($0.05 per diluted share). Cash was $15.4 million and long-term debt $46.5 million. After quarter-end, Sanara said it expects to be acquired by MIMEDX, subject to closing conditions.
6 min readMiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
4 min readTransformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...
4 min readMiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.
4 min readMiMedx Group Inc. (MDXG) reported a Q2 loss of $14.8 million, or 10 cents per share. Adjusted for non-recurring items, it posted a 5 cents per share loss. Revenue was $64.4 million. The company expects full-year revenue of $260 million to $290 million.
2 min readBiotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
3 min read
